Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Ultrafine Concentrated Ambient Particles

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01257191Phase 1Completed

A Study to Compare the Effects of Different Sized Particles on Cells in the Nose

Showing all 1 trials

Research Network

Common Treatments

  • Ultrafine Concentrated Ambient Particles1
  • Carbon Black1
  • Fine Concentrated Ambient Particles1
  • Diesel Exhaust Particles1
  • Saline1

Active Sponsors

  • National Institute Of Allergy And Infectious Diseases Niaid1
  • University Of California Los Angeles1

Related Conditions

  • Hypersensitivity Immediate1

Activity Timeline